Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.

Keywords

Mathematics, Field (mathematics), Calculus (dental), Geography, Pure mathematics

References

• Chronic myelomonocytic leukemia: myeloproliferative variant.Francesco Onida, Miloslav Beran — 2004
• What's going on 造血器腫瘍 A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. N Engl J Med. 2005; 352: 1779-90. PMID:15858187.--慢性骨髄増殖性疾患においてJAK2遺伝子の変異が高頻度にみられることを示した論文智洋 松山 — 2005
• Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.Philippe Guardiola, Jeanne E. Anderson, Giuseppe Bandini — 1999
• Prognosis in transplant‐eligible patients with agnogenic myeloid metaplasiaDavid Dingli, Susan M. Schwager, Ruben A. Mesa — 2006
• Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groupsFrancisco Cervantes, Giovanni Barosi, Jean‐Loup Demory — 1998
• The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid MetaplasiaGiovanni Barosi, Achille Ambrosetti, Carlo Finelli — 1999
• JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemiaMuhammad Farid Johan, Anne Goodeve, David Bowen — 2005
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.Róbert Královics, Francesco Passamonti, Andreas Buser — 2005
• Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.Francesco Onida, Hagop M. Kantarjian, Terry L. Smith — 2002
• Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patientsGiuseppe Visani, Carlo Finelli, U. Castelli — 1990
• Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.Ayalew Tefferi, Gary Gilliland — 2006
• Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosisNicolaus Kröger, Tatjana Zabelina, Heike Schieder — 2005
• Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995Ruben A. Mesa, Murray N. Silverstein, Steven J. Jacobsen — 1999
• Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosisFrancisco Cervantes, Arturo Pereira, Jordi Esteve — 1997
• A prognostic classification of myelofibrosis with myeloid metaplasiaGiovanni Barosi, Carlo Berzuini, Lucio N. Liberato — 1988
• Pathogenesis of myelofibrosis with myeloid metaplasia.Ayalew Tefferi — 2005
• Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi, David Dingli, Chin‐Yang Li — 2005
• Idiopathic myelofibrosis: pathogenesis, natural history and management.John T. Reilly — 1997
• Prognostic significance of monocytosis in patients with myeloproliferative disordersMiloslav Beran, Yu Shen, Francesco Onida — 2006
• The World Health Organization (WHO) classification of the myeloid neoplasms.James W. Vardiman, Nancy L. Harris, Richard D. Brunning — 2002

Cited by

• JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsMassimo Panzarella — 2008
• CMML: Clinical and molecular aspectsЦветков Василий Александрович — 2017
• Determinantes celulares, plasmáticos y genéticos de riesgo de trombosis y hemorragia en pacientes con neoplasias mieloproliferativas crónicas filadelfia negativoM. Belmonte, M. José — 2010
• Absolute monocytosis at diagnosis correlates with survival in diffuse large B‐cell lymphoma—possible link with monocytic myeloid‐derived suppressor cellsTamar Tadmor, Rona Fell, Aaron Polliack — 2013
• Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosisVictor T. Chang, Clara R. Yook, Pranela Rameshwar — 2013
• Risk factors for leukemic transformation in patients with primary myelofibrosisJocelin Huang, Chin‐Yang Li, Ruben A. Mesa — 2008
• An Immune Dysregulation in MPNGiovanni Barosi — 2014
• Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current PracticeDorothée Selimoglu‐Buet, Éric Solary — 2014
• Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in MyelofibrosisHaefaa Alchalby, Nicolaus Kröger — 2010
• Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.Paola Guglielmelli, Giovanni Barosi, Giorgina Specchia — 2009
• Choosing between stem cell therapy and drugs in myelofibrosisNicolaus Kröger, Ruben A. Mesa — 2008
• Does monocyte count have prognostic significance in cancer?Tamar Tadmor — 2013
• Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Fábio Pires de Souza Santos, Hagop M. Kantarjian, Nitin Jain — 2010
• Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemiaHans Kreipe, Kais Hussein, Gudrun Göhring — 2011
• Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapyAyalew Tefferi — 2008
• JAK2 inhibitors: A reality? A hope?Effrosyni Apostolidou, Hagop M. Kantarjian, Srđan Verstovšek — 2009
• Age and platelet count are IPSS‐independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survivalMrinal M. Patnaik, Domenica Caramazza, Naseema Gangat — 2010
• Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.Alexander S. Christensen, Jonas Bech Møller, Hans Carl Hasselbalch — 2014
• Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.Nora P. Goette, Paola R. Lev, Paula G. Heller — 2010
• Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of TransplantationFrancisco Cervantes, Mireia Camós, Rolando Vallansot — 2008

Related papers

No related papers recorded.